Sanofi Consumer Healthcare India Ltd (SANOFICONR) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 24, 2026 3 min read

Sanofi Consumer Healthcare India is navigating a transition phase focused on reigniting growth across its core allergy, pain, and Vitamin D portfolios following a period of product recalls. Investors will be watching for signs of sustained domestic recovery and the impact of ongoing brand investments on the company's margin profile.

Quick Details

Results date	July 28, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 229.2 Cr
Previous quarter PAT	Rs. 67.8 Cr
Market cap	Rs. 10714.08 Cr
CMP	Rs. 4652.1

Sanofi Consumer Healthcare India Ltd Q1 Results Date and Time

The board meeting is scheduled for July 28, 2026, to consider the Q1 and H1 FY27 financial results.

What to expect from Sanofi Consumer Healthcare India Ltd's Q1 FY27 results

The company enters Q1 FY27 with a strong demand tailwind, as the Indian Pharmaceutical Market posted 12.1% YoY growth in May 2026. Management continues to prioritize the reignition of profitable growth, with A&P investments ramping up since mid-2025 to rebuild brand equity across key segments like allergy and pain. The ~10-11% YoY depreciation of the rupee during the quarter serves as a material tailwind for the company's export business, which contributed 19% of total turnover in FY25. Ongoing recovery from 2024 product recalls remains a focus, with underlying domestic growth excluding recall impacts recorded at 11% in the previous quarter. The upcoming call will likely address the trajectory of A&P spending and the impact of the new auditor transition effective May 25, 2026.

Key Things To Watch

Performance vs Guidance Tracking: Tracking progress against the company's stated aspirational targets for 2026.

Double face-to-face doctor reach — target by 2026 — status pending
Scale digital HCP reach to 50,000 — open-ended — status pending
2x direct retail coverage — open-ended — status pending

Strategic Updates and Innovation: Monitoring the execution of the company's brand-led growth strategy.

A&P spend trajectory — management indicated investments started in Q2 of the prior year and are continuing
Innovation pipeline — update on new product launches following the Allegra D launch
Field force productivity — results from the one touch app and AI-enabled content generation

Risks and headwinds to monitor: Operational and regulatory factors impacting the current quarter.

Product recall legacy — status of sales recovery for Depura, Allegra Suspension, and Combiflam Suspension
Auditor transition — first quarter reporting under Price Waterhouse & Co following the resignation of the previous auditor
OTC regulatory environment — monitoring impact of the 13th Drugs (Prices Control) Amendment Order, 2026

Frequently Asked Questions

How did Sanofi Consumer Healthcare's domestic sales perform in the previous quarter?

Domestic sales grew 15.5% YoY in Q4 FY26, benefiting from the successful relaunch of previously recalled products. Excluding the impact of these recalls, the underlying domestic growth was 11%.

What is the company's current stance on providing growth guidance?

The CFO has explicitly stated that the company has a policy against providing forward-looking assumptions or growth guidance. Management instead focuses on operational goals like expanding HCP reach and retail coverage.

What impact did the rupee depreciation have on the company's export business?

The rupee depreciated approximately 10-11% YoY during the quarter, which acts as a tailwind for the company's export revenue. Exports accounted for 19% of the company's total turnover in FY25.